期刊文献+

前列腺癌组织中TGF-β1和wt-p53基因mRNA的表达及意义 被引量:2

下载PDF
导出
摘要 目的探讨前列腺癌(PCa)组织中转化生长因子-β1(TGF-β1)、野生型p53(wt-p53)基因的表达及意义。方法应用RT-PCR技术检测正常前列腺、PCa组织和癌旁组织中TGF-β1、wt-p53mRNA的表达情况。结果正常前列腺外腺和癌旁组织间的TGF-β1、wt-p53表达水平相似(P>0.05);PCa组织中TGF-β1和wt-p53表达与正常PCa组织和癌旁组织相比差异显著(P<0.01);已有远处转移灶的PCa组织中TGF-β1和wt-p53表达与无转移者有统计学差异(P<0.01)。结论测定TGF-β1与wt-p53表达可协助PCa的诊断和评估预后。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2010年第7期878-880,共3页 Chinese Journal of Gerontology
基金 国家科学技术部国际科技合作重点项目(2004DFB02000)
  • 引文网络
  • 相关文献

参考文献9

  • 1王尧,王伟华,计国义,范海涛.吉林地区超声引导经直肠前列腺活检513例报告[J].中国老年学杂志,2008,28(19):1926-1927. 被引量:3
  • 2Pardali K,Moustakas A.Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer[J].Biochim Biophys Acta,2007;1775(1):21-62.
  • 3Bae DS,Blazanin N,Licata M,et al.Tumor suppressor and oncogene actions of TGFbeta 1 occur early in skin carcinogenesis and are mediated by Smad3[J].Mol Carcinog,2009;48(5):441-53.
  • 4丁国芳,李继承,徐银峰.前列腺癌nm23H1mRNA、TGF-β1mRNA表达及其与肿瘤转移、生存率的相关性研究[J].分子细胞生物学报,2006,39(6):544-552. 被引量:12
  • 5Prud'homme GJ.Pathobiology of transforming growth factor beta in cancer,fibrosis and immunologic disease,and therapeutic considerations[J].Lab Invest,2007;87(11):1077-91.
  • 6Nayak SK,Panesar PS,Kumar H.p53-Induced apoptosis and inhibitors of p53[J].Curr Med Chem,2009;16(21):2627-40.
  • 7Adhikari AS,Iwakuma T.Mutant p53 gain of oncogenic function:in vivo evidence,mechanism of action and its clinical implications[J].Fukuoka Igaku Zasshi,2009;100(6):217-28.
  • 8Qian J,Hirasawa K,Bostwick DG,et al.Loss of p53 and c-myc overrepresentation in stage T(2-3) N(1-3)M(0) prostate cancer are potential markers for cancer progression[J].Mod Pathol,2002;15(1):35-44.
  • 9Athar M,Back JH,Kopelovich L,et al.Multiple molecular targets of resveratrol:Anti-carcinogenic mechanisms[J].Arch Biochem Biophys,2009;486(2):95-102.

二级参考文献18

  • 1王健,江怡,唐崎,顾炯,刘定益,祝宇,张羽中宇,王名伟.超声引导经直肠前列腺穿刺活检术(附192例报告)[J].中国男科学杂志,2005,19(2):31-33. 被引量:16
  • 2Stravodimos, K., C. Constantinides, T. Manousakas, C.Pavlaki, D. Pantazopoulos, A. Giannopoulos, & C. Dimopoulos, 2000, Immunohistochemical expression of transforming growth factor beta 1 and nm-23H1 antioncogene in prostate cancer: divergent correlation with clinicopathological parameters. A nticancer Res., 20 (5) :3823-3828.
  • 3Roberts,A & Spom, M., 1996,Transforming growth factor β in molecular and cellular biology of wound repair,PAF Clank, Med. New York, Plenum Press., 43 (15) :275-308.
  • 4Jacquemier, J., M. P. Mathoulin-Portier, R. Valtola, E.Charafe -Jauffret, J. Geneix, G.Houvenaeghel, B. Puig,V.J. Bardou,J. Hassoun,P. Viens & D. Birnbaum,2000,Prognosis of breast carcinoma lymphangiogenesis evaluated by immunohistochemicnal investigation of vascular-endothelial-growth-factor recptor 3. Int. J. Cancer, 89(1): 69-73.
  • 5Akagi, K., Y. Ikeda, M. Miyazaki,T. Abe, J. Kinoshita,Y. Maehara & K. Sugimachi, 2000, Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br. J. Cancer, 83: 887-891.
  • 6Weidner, N., J. P. Semple,W. R. Welch & J. Folkman,1991 ,Tumor angiogenesis and metastasis : correlation in invasive breast carcinoma. N. Engl. J. Med, 324: 1-8.
  • 7Kaplan, E. L & P. Meier., 1958, Parametric estimation from incomplete observation. J. Am. Star. Assoc. 53: 457 -481.
  • 8Steeg,P. S.,G. Bevilacqua & L. Kopper, 1988,Evidence for a novel gene associated with low tumor metastatic potential. J. Natl. Canaer.Inst, 80(3): 200-204.
  • 9Russell, R. L., A. N. Pedersen, J. Kantor, K. Geisinger,R. Long, N. Zbieranski, A. Townsend, B. Shelton, N.Brunne. & T.E. Kute, 1998, Relationship of nm23 to proteolytic factor,proliferation and motility in breast cancer tissues and cell lines. Br. J. Cancer, 78(6) : 710-717.
  • 10Shariat,S. F,J. H. Kim,B. Andrews, M. W. Kattan, T. M. Wheeler,I. Y. Kim,S. P. Lemer & S. P. L.Slawin, 2001, Preoperative plasma levels of transforming growth factor beta (1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer, 92(12):2985-2992.

共引文献12

同被引文献17

  • 1孟庆超,王禾,于磊,孟平,王映梅,马福成.Bag-1及Bcl-2在前列腺癌组织中的表达及意义[J].现代肿瘤医学,2007,15(3):366-368. 被引量:9
  • 2Nephew KP, Huang TH. Epigenetic gene silencing in cancer initiation and progression [ J ]. Cancer Lett,2003,190 (2) : 125 - 133.
  • 3Laird PW. Cancer epigenetics [J]. Hum Mol Genet, 2005, 14 (1) :65 -76.
  • 4Porkka KP, Pfeiffer M J, Waltering KK, et al. MicroRNA expression profiling in prostate cancer [ J ]. Cancer Research,2007,67 : 6130- 6135.
  • 5Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers[J]. Nature, 2005,435 (7043) : 834 - 838.
  • 6Bonci D, Coppola V. The miR - 15a - miR - 16 - 1 cluster controis prostate cancer by targeting multiple oncogenic activities [J]. Nature Medicine,2008, 14 : 1271 - 1277.
  • 7Noonan EJ. miR -449a targets HDAC - 1 and induces growth arrest in prostate cancer[J]. Oncogene,2009, 28:1714 -1724.
  • 8Frankel LB, Christoffersen NR, Jacobsen A, et al. Programmed cell death 4 (PDCIM) is an important functional target of the microRNA miR-21 in breast cancer cells[J]. J Biol Chem,2008, 283: 1026 - 1033.
  • 9Tong AW, Fulgham P, Jay C, et al. MicroRNA profile analysis of human prostate cancers[J]. Gradalis, 2009,3:22.
  • 10周静,李进,林戈,卢光琇.Wnt3a和Activin A共同促进人胚胎干细胞向限定性内胚层细胞分化[J].西北农林科技大学学报(自然科学版),2010,38(4):37-41. 被引量:6

引证文献2

二级引证文献3

;
使用帮助 返回顶部